Eastern equine encephalitis virus structural polyprotein (EEEV antigen)

Eastern equine encephalitis virus (EEEV) is a highly pathogenic, mosquito-borne alphavirus that causes severe encephalitis in humans and equines, with a high case-fatality rate and significant long-term neurological sequelae (CDC, 2023). The primary therapeutic targets are the viral structural antigens, specifically the E1 and E2 glycoproteins, which form heterodimeric spikes on the viral envelope (Sun et al., 2020). The E2 protein is responsible for initial attachment to host cell receptors, such as Mxra8, while the E1 protein facilitates pH-dependent membrane fusion within host endosomes to release the viral genome (Adams et al., 2021). Because these proteins are exposed on the virion surface, they are the principal targets for the host's neutralizing antibody response and are the focus of vaccine and monoclonal antibody development (NIH, 2021). Currently, there are no FDA-approved vaccines or antiviral drugs for EEEV, making the development of therapies targeting these antigens a high priority for public health and biodefense. Research is ongoing into recombinant vaccines and potent neutralizing antibodies that can provide post-exposure prophylaxis or treatment.

Other names

EEEV E1 glycoproteinEEEV E2 glycoproteinEEEV envelope proteinsEastern equine encephalitis virus structural proteinsEEEV E1/E2 heterodimer

Neutralization of viral particles by binding to E1 or E2 glycoproteins, thereby preventing receptor attachment or inhibiting pH-dependent membrane fusion within host endosomes.